Danske Bank’s CervoMed CRVO Stock Holding History

Danske Bank’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3	Hold	1	–	–	﹤0.01%	1110
2026 Q1	$4	Hold	1	–	–	﹤0.01%	1113
2025 Q4	$8	Hold	1	–	–	﹤0.01%	1487
2025 Q3	$8	Hold	1	–	–	﹤0.01%	1423
2025 Q2	$6	Hold	1	–	–	﹤0.01%	1473
2025 Q1	$9	Hold	1	–	–	﹤0.01%	1320
2024 Q4	$2	Hold	1	–	–	﹤0.01%	1378
2024 Q3	$15	Buy	+1	New	+$15	﹤0.01%	1512

Other funds holding CRVO

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BAM

Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return

CFG

Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

TDC

Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return

Danske Bank's CRVO Position: Q2 2026 in Review

Danske Bank held its CervoMed (CRVO) position steady in Q2 2026 at 1 share worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #1110.

Danske Bank first reported a position in CRVO in Q3 2024 and has held it in 8 quarters since. The position peaked at $15 in Q3 2024. 37 funds tracked by Wall St. Rank hold CRVO as of Q2 2026.

Danske Bank held 1 share of CervoMed worth $3 as of Q2 2026.
Danske Bank left its CervoMed share count unchanged in Q2 2026.
CervoMed made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1110 holding.
Danske Bank first reported a position in CervoMed in Q3 2024 and has held it in 8 quarters since.
Danske Bank's CervoMed position peaked at $15 in Q3 2024.
37 funds tracked by Wall St. Rank held CervoMed as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.